Cotrimoxazol to prevent malaria in HIV-infected pregnant women in Sub-Saharan Africa

Effectiveness of Trimethoprim-Sulfamethoxazole to prevent malaria in HIV-infected pregnant women in P. falciparum-endemic Sub-Saharan Africa: a randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN98835811

Enrollment

300

Registered

2012-09-27

Start date

2009-01-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria HIV vertical transmission Infections and Infestations Plasmodium falciparum malaria

Interventions

Women who volunteered were randomized to receive either daily 80/400mg trimethoprim-sulfamethoxazole (CMX) or intermittent preventive treatment (IPT) with 1000/50mg sulfadoxine-pyrimethamine (SP) as f

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. HIV1 2. Women 200/mm3 4. Hb >7 g/L

Exclusion criteria

Exclusion criteria: 1. Age<15 2. HIV2 or HIV1+2 3. Allergy or ongoing sulfamides treatment

Design outcomes

Primary

Measure	Time frame
Incidence of malaria during pregnancy, calculated as the number of malaria events per person year.	—

Secondary

Measure	Time frame
1. Blood parasitaemia in women and new-born 2. Treatment tolerance 3. Pregnancy outcome 4. Birth weight 5. Placental malarial infection	—

Countries

Togo

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 10, 2026